Product category:
Pharmaceutical Processing News
News Release from: BioProcessors | Subject: SimCell
Edited by the Processingtalk Editorial
Team on 15 September 2005
The SimCell platform was selected by
Novo Nordisk
Having identified rapid, early process development as critical to the success of their biologics programmes, the SimCell MicroBioreactor system has been adopted by Novo Nordisk
Having identified rapid, early process development as critical to the success of their biologics programmes, the SimCell MicroBioreactor system has been adopted by Novo Nordisk, for high-throughput mammalian cell culture process development BioProcessors has announced the sale of the SimCell MicroBioreactor Automation Management System to Novo Nordisk, having successfully completed platform evaluation trials
This article was originally published on Processingtalk on 19 Jul 2005 at 8.00am (UK)
Related stories
BioProcessors SimCell MicroBioreactor progresses
The Biochemical XIV Show disclosed the completion of an important phase of a long-term joint project with Amgen aimed at evaluating the BioProcessors SimCell MicroBioreactor technology
High throughput scaled-down bioreactor tool
Invitrogen adds BioProcessors SimCell high throughput automated cell culture microbioreactor system for process development services
The SimCell platform will enable Novo Nordisk to rapidly accelerate their mammalian cell culture process development initiatives.
As a result of the joint effort, the companies demonstrated the predictability and scalability of the BioProcessors MicroBioreactor Array, and a high-throughput robotic workstation to conventional bioreactor systems.
BioProcessors SimCell MicroBioreactor solutions enable biotechnology and pharmaceutical companies to increase cell culture experiment capacity by orders-of-magnitude with greater data quality, faster cycles and lower costs than conventional biopharmaceutical processing methods.
"Existing high-throughput systems emphasise miniaturisation at the expense of performance and data generation, in most cases limiting the usefulness of such high-throughput tools to only a screening function," said Dr Andrey Zarur, CEO and President, BioProcessors: "This paradox is clearly visible in the area of cell culture where 96 well plates and shake flasks are used as high-throughput screens for cell line selection, media and process optimisation.
In all but the simplest of processes these systems are at best only a crude approximation of a working bioreactor and hence provide little reliably scalable cell culture process information.
Poor scalability and, in the case of shake flasks, insufficient experimental power to provide complete full factorial process development DOEs limits researchers real-time ability to identify robust processes capable of operating at their global optima," Dr Zarur added.
BioProcessors SimCell MicroBioreactors address this process development "data gap" by integrating microfluidics with remote monitoring and control, enabling high-throughput process development through the miniaturisation of bioreactors that accurately simulate full scale manufacturing processes.
• BioProcessors: contact details and other news
• Email this article to a colleague
• Register for the free Processingtalk email newsletter
• Processingtalk Home Page
Search the Pro-Talk network of sites
